Skip to main content

Table 1 Patient characteristics for colesevelam HCL users

From: Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record

Characteristic All T2DM patients (N = 1747)
Age (n, %)  
 18-44 years 132 (7.56%)
 45-49 years 149 (8.53%)
 50-54 years 208 (11.91%)
 55-59 years 299 (17.12%)
 60-64 years 300 (17.17%)
 65-69 years 263 (15.05%)
 70-74 years 195 (11.16%)
 75-79 years 126 (7.21%)
 ≥ 80 years 75 (4.29%)
Sex (n, %)  
 Female 1018 (58.27%)
 Male 729 (41.73%)
Race (n, %)  
 White 938 (53.69%)
 Black 160 (9.16%)
 Asian 6 (0.34%)
 Other 47 (2.69%)
 Unknown 596 (34.12%)
Insurance Type (n, %)  
 Commercial 454 (25.99%)
 Medicare 637 (36.46%)
 Medicaid 24 (1.37%)
 Self-Pay 10 (0.57%)
 Other 8 (0.46%)
 Unknown 614 (35.15%)
Region (n, %)  
 Midwest 350 (20.03%)
 Northeast 433 (24.79%)
 South 847 (48.48%)
 West 117 (6.70%)
Baseline A1c Values (mean, SD) 8.25 (1.32)
Prior T2DM Treatments (n, %)  
 Biguanide 266 (15.23%)
 Insulin 506 (28.96%)
 Sulfonylurea 231 (13.22%)
 Thiazolidinediones 118 (6.75%)
 DPP-4 inhibitor 63 (3.61%)
 Other Miscellaneous 64 (3.66%)
Number of Prior T2DM Treatments (n, %)  
 0 808 (46.25%)
 1 687 (39.32%)
 2 204 (11.68%)
 3 42 (2.40%)
 ≥4 6 (0.34%)